Compare ARK Genomic Revolution ETF (ARKG) vs MasterCard Inc (MA) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ARK Genomic Revolution ETF vs MasterCard Inc — how do they compare? ARK Genomic Revolution ETF trades at $40.95, while MasterCard Inc trades at $527.06 (market cap $465.42B). The key difference: MasterCard Inc pays a 0.66% dividend while ARK Genomic Revolution ETF pays none, and ARK Genomic Revolution ETF is trading nearer its 52-week high, MasterCard Inc nearer its low. Which is the better fit depends on your goals.
| ARKG | MA | |
|---|---|---|
Sector | Sector/Thematic | Consumer Cyclical |
52-Week High | $43.57 | $598.96 |
52-Week Low | $23.09 | $471.55 |
Market Cap | — | $465.42B |
Volume | — | 4,635,698 |
Enterprise Value | — | $476.16B |
Dividend Yield | — | 0.66% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ARKG trades at $41.32, down 3.91% today, with a bullish technical signal driven by moving averages. Recent news highlights biotech ETF strength in June 2026, fueled by strong earnings, M&A activity, and AI-driven drug discovery optimism. Key support lies at $40, with resistance at $44.
The outlook remains positive given sector tailwinds, but risks include regulatory hurdles and market volatility. Investor sentiment is buoyed by industry growth catalysts, though selective investment approaches are noted by analysts.
Mastercard (MA) trades at $526.74, up 0.68% with a bullish technical outlook. The stock shows strong fundamentals with consistent earnings beats, 45.88% net margins, and robust revenue growth from $22.2B in 2022 to $32.8B in 2025. Analyst consensus is strongly bullish with a $637.67 price target and 79% buy ratings. Recent institutional buying and dividend payments of $0.87 per share support positive sentiment.
Mastercard presents a compelling growth opportunity with expanding global payments infrastructure and AI integration. Risks include payment disruption from stablecoins and competitive pressures. The stock trades at a premium valuation (P/E 30.48) but justifies it through superior profitability and market leadership position.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ARK Genomic Revolution ETF
ARKG is an actively managed ETF that invests in the genomic revolution. It focuses on companies leading in gene editing, CRISPR technology, therapeutics, and molecular diagnostics, including firms like CRISPR Therapeutics and Tempus AI.
Read more on ARKG →About MasterCard Inc
Mastercard Incorporated provides financial transaction processing services. The Company offers payment processing services for credit and debit cards, electronic cash, automated teller machines, and travelers checks. Mastercard serves customers worldwide.
Read more on MA →
